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Laryngeal Preservation Strategies in
Locally Advanced Laryngeal and
Hypopharyngeal Cancers
Athanassios Argiris 1* and Jean Louis Lefebvre 2
1Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States, 2Centre Oscar Lambret,
Lille, France
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal
squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive
radiotherapy (RT). The development of induction cisplatin plus 5-fluorouracil (PF) and the
correlation between chemosensitivity and radiosensitivity in previously untreated patients
opened a new era of treatment aiming at laryngeal preservation (LP). The fundamental
concept was to employ induction PF in order to select patients for subsequent treatment
with either TL or RT according to tumor response to PF. The first two trials (VALGSG
for laryngeal SCC and EORTC 24891 for hypopharyngeal SCC) concluded that such an
approach could preserve nearly 60% of larynx without deleterious impact on survival. The
EORTC 24954 trial compared 4 cycles of induction PF followed by RT in good responders
vs. alternating PF-RT in laryngeal and hypopharyngeal SCC. There was no significant
difference in 5-year overall survival with a functional larynx between the two arms (31 vs.
35%). The GORTEC 2000-01 trial compared induction PF to induction PF plus docetaxel
(TPF) both followed by RT in good responders in larynx and hypopharynx SCC. The
5-year LP was significantly higher in the TPF arm (60 vs. 39%) but without a difference in
survival. The RTOG91-11 trial compared induction PF followed by RT in good responders
vs. concurrent chemoradiotherapy (chemo-RT) vs. RT alone in laryngeal SCC. There was
no significant difference in 5-year laryngectomy-free survival between the patients treated
with induction chemotherapy (44%) vs. those treated with chemo-RT (47%), both being
superior to RT alone (34%). At 5 years, LP was superior with chemo-RT: 84 vs. 71% with
induction PF. Two phase II trials explored the role of cetuximab (E) in LP in laryngeal and
hypopharyngeal SCC. The TREMPLIN trial compared RT+E or chemo-RT (RT + P) after
TPF. The DeLOS-II trial compared TPE followed by RT+E vs. TP followed by RT. However,
these trials failed to indicate an advantage for the incorporation of E in the treatment
paradigm. To date, two approaches for LP have been validated: induction TPF followed
by RT for laryngeal and hypopharyngeal SCC and concurrent chemo-RT for laryngeal
SCC. An ongoing trial (SALTORL) is comparing these two approaches, induction TPF
and chemo-RT, in laryngeal/ hypopharyngeal SCC.
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INTRODUCTION
Since the beginning of the twentieth. century two major options
were available for the treatment of locally advanced laryngeal
and hypopharyngeal squamous cell carcinomas (SCC): definitive
radiation therapy (RT) with salvage surgery reserved in case of
local failure or total laryngectomy with postoperative RT. The
indications for each approach varied according to institutional
policies. Since no randomized trials with these two approaches
were available at that time and results were derived from
retrospective analyses comparisons of outcomes and the merits
of each treatment strategy were highly debatable.
For long, clinical investigations aimed at extending the
indications of partial laryngectomy or exploring different
protocols of RT using altered fractionation schedules or
concurrent radiosensitizers. These efforts did not notably alter
the main treatment approaches (i.e., surgical vs. non-surgical) in
laryngeal and hypopharyngeal SCC. At that time chemotherapy
was mainly used for the palliative treatment of head and
neck SCC.
An important milestone was the publication in 1983 by
the Wayne State University of its experience with induction
chemotherapy using cisplatin and 5-fluorouracil (PF) in
previously untreated patients with head and neck cancers. In
a series of 35 patients treated with three cycles of induction
chemotherapy with PF, 94% demonstrated a tumor reduction
of at least 50 and 63% had a complete clinical disappearance
of the disease (1). In another report on 60 patients treated by
induction cisplatin-based chemotherapy it appeared that the 42
patients who had demonstrated a tumor response over 50%, 97%
of them were controlled by a subsequent RT opposite to 6% of
the 18 patients with a tumor reduction below 50% who were
controlled by a subsequent RT (2). For the first time, induction
chemotherapy was shown to have a potential role in curative
intent treatment and could assist in selecting good candidates for
subsequent definitive RT. These data re-opened the discussion
on the treatment of advanced laryngeal and hypopharyngeal
cancers. Two approaches were under discussion: (a) induction
PF followed by RT in good responders (tumor regression of at
least 50%) or by surgery in other patients and (b) upfront surgery
and postoperative RT. Later on, the results of a large meta-
analysis showed that concurrent chemoradiotherapy (CRT), in
particular with cisplatin-based regimens, achieved better results
in terms of survival than induction PF followed by RT (3).
Finally, the introduction of induction PF plus docetaxel (TPF
protocol) and the use of cetuximab enriched the potential clinical
research questions. Several clinical protocols explored induction
chemotherapy, concurrent CRT, and the combination of these
two approaches.
THE FIRST TRIALS WITH INDUCTION
CHEMOTHERAPY
The main objective of these phase III trials was to compare
upfront total laryngectomy with postoperative RT with an
experimental approach with induction PF followed in responders
by RT (with salvage surgery if required for failures after RT) or by
a total laryngectomy with postoperative RT in non-responders.
Each cycle of chemotherapy consisted of cisplatin 100 mg/m2
on day 1 followed by 5-fluorouracil 1,000 mg/m2 /day for 5 days
and was delivered every 3 weeks. Definitive RT was administered
to a total dose of 70Gy and postoperative RT to a total dose of
60Gy. “Responders” to chemotherapy were defined as patients
with a tumor regression of at least 50%.
The primary end-point was under discussion as these first
trials were designed. Published data from surgical series provided
good results in terms of survival and locoregional control but on
selected patients (operable patients with resectable disease). The
reported survival rates after definitive RTwere lower but included
patients with worse prognosis (e.g., unresectable or inoperable).
To validate the concept of laryngeal preservation the prerequisite
was to assure that there was no deleterious impact on disease
control and survival. Therefore, the two first trials had survival as
their primary end-point. However improving overall survival has
not been a primary objective given the impact of salvage surgery
on overall survival.
The Veterans Administration Larynx
Cancer Study Group (VALCSG) Trial
In the United States, the department of VALCSG conducted
this randomized trial in 332 laryngeal cancer patients (166 in
the surgical control arm and 166 in the experimental arm)
(4). The experimental treatment consisted of two cycles of PF
followed in responders by a third cycle and RT or surgery and
postoperative RT in non-responders). Overall survival was the
primary endpoint. At a median follow-up of 33 months, the 2-
year survival was 68% in both treatment arms (95% Confidence
Interval [CI]: 60–75% in the surgery arm vs. 60–76% in the
chemotherapy arm, P = 0.9846) and the larynx was preserved in
64% of the patients in the experimental arm. In the chemotherapy
arm, salvage laryngectomies were indicated significantly more
often in patients with T4 diseases vs. those with T3 disease (P =
0.001). Of note distant metastases were observed less frequently
in the chemotherapy arm (4).
The European Organization for Research
and Treatment of Cancer (EORTC) 24891
Trial
In Europe, the EORTC Head and Neck Cooperative
Group conducted a similar trial in patients with advanced
hypopharyngeal and lateral epilarynx tumors requiring a total
laryngectomy (5). In this EORTC 24891 trial, 194 previously
untreated patients were enrolled.
Chemotherapy consisted of 100 mg/m2 given intravenously
over a 1-h period followed by fluorouracil 1,000/m2 /day given
as a 120-h infusion over 5 days (total dose 5,000 mg/m2). A
partial response (PR) after two or three cycles of chemotherapy
was required to receive RT. The primary endpoint was overall
survival in terms of non-inferiority in the experimental arm
with a hazard ratio (HR) ≤ 1.43. In the first evaluation the
median duration of survival was 25 months in the immediate-
surgery arm and 44 months in the induction-chemotherapy arm
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and, since the observed hazard ratio was 0.86 (log-rank test,
P = 0.006), which was significantly <1.43, the two treatments
were judged to be equivalent. The 3- and 5-year estimates of
retaining a functional larynx in patients treated in the induction-
chemotherapy arm were 42% (95% CI: 31–53%) and 35% (95%
CI: 22–48%), respectively (5).
These results were confirmed by long-term evaluation. At a
median follow-up of 10.5 years, the 5-year and 10-year overall
survival rates were, respectively, 32.6% (95% CI: 23.0–42.1%) and
13.8% (95% CI: 6.1–21.6%) in the surgery arm vs. 38.0% (95% CI:
28.4–47.6%) and 13.1% (95%CI: 5.6–20.6%) in the chemotherapy
arm. In 37 patients still alive at 5 years in the chemotherapy arm,
22 (59.5%) had retained a normal larynx (6). It is noteworthy that
distant metastases were less frequent in the chemotherapy arm as
in the American trial.
Conclusions After These Trials
These two trials showed that the concept could be validated,
both for laryngeal and hypopharyngeal cancers, as the larynx
could be preserved in about two-thirds of the patients without
compromising survival or disease control. This clinical research
paradigm, therefore, could continue with the primary end-
point being laryngeal preservation. However, the definition of
“laryngeal preservation” had to be clearly defined.
Laryngeal preservationmay be defined by only one parameter:
larynx in place (i.e., no laryngectomy). A more comprehensive
one is to consider both the organ and its function: no
laryngectomy, no long-term tracheotomy, and no long-term
feeding tube, which implies also that local control is obtained.
As survival is an important issue, it may also be integrated in
the definition of laryngectomy-free survival or survival with a
functional larynx in place.
In 2009, a group of experts fine-tuned the definition
of laryngeal preservation taking into account all parameters
participating to the real benefit for the patients. They elaborated
the “laryngoesophageal dysfunction-free survival” that combined
as events: death, local failure, salvage laryngectomy, and
tracheotomy or feeding tube at 2 years or later (7, 8).
The EORTC 24954 Trial
The EORTC Head and Neck and Radiotherapy Oncology
Cooperative Groups designed a randomized trial in order to
compare two different schedules for delivering more cycles of
chemotherapy: a sequential schedule like the one used in the
previous EORTC 24891 trial vs. an alternating one as described
by Merlano (9). The sequential arm consisted of two cycles of
PF with the same doses and administration as in the 24891 trial.
After 2 cycles responders received two additional cycles of PF and
were then treated with RT at a dose of 70Gy. The non-responders
were treated by total laryngectomy and postoperative RT. In the
alternating arm, patients received on weeks 1, 4, 7, and 10 a cycle
of chemotherapy consisting of cisplatin at a dose of 20 mg/m2
per day on days 1–5 (for a total dose of 100 mg/m2) and 5-
fluorouracil by bolus infusion at a dose of 200 mg/m2 per day
on days 1–5 (for a total of 1,000 mg/m2). During the three 2-
week intervals patients were treated by RT at a dose of 20Gy
per course for a total of 60Gy. As a result, the total doses of 5-
fluorouracil and of RT were lower in the alternating arm. A total
of 450 patients were enrolled in this trial (224 to the sequential
arm and 226 to the alternating arm).
For the first evaluation the median follow-up was 6.5 years.
Survival with a functional larynx was similar in the sequential and
alternating arms (hazard ratio of death and/or event= 0.85, (95%
CI: 0.68–1.06), as were median overall survival (4.4 and 5.1 years,
respectively). Grade 3 or 4 mucositis occurred in 64 (32%) of the
200 patients in the sequential arm who received radiotherapy and
in 47 (21%) of the 220 patients in the alternating arm. Late severe
oedema and/or fibrosis was observed in 32 (16%) patients in the
sequential arm and in 25 (11%) in the alternating arm (10).
For the long-term evaluation, the median follow-up was
10.2 years. Ten-year survival with a functional larynx (primary
end-point) and overall survival were similar in the sequential
and alternating arms (18.7 and 33.6% vs. 18.3 and 31.6%,
respectively). Late toxicity was also similar even if there was
a trend for higher laryngeal preservation and better laryngeal
function in the alternating arm (11). The lower doses of
chemotherapy and RT in the alternating arm may explain the
better tolerance to treatment. However, due to the organizational
difficulties when delivering such an alternating schedule in daily
practice, it is rarely used.
The Groupe Oncologie Radiotherapie Tete
Et Cou (GORTEC) 2000-01 Trial With
Cisplatin, 5-FU, Docetaxel
Two large randomized trials (12, 13) had shown that adding
docetaxel to cisplatin fluorouracil (the so-called TPF regimen)
before RT (or CRT) resulted in a significantly higher survival
compared to that observed with the doublet regimen (PF).
In France, in order to assess whether induction TPF could
provide better results than induction PF in the frame of laryngeal
preservation, the GORTEC conducted a two-arm randomized
trial in 220 patients with a locally advanced laryngeal or
hypopharyngeal cancer eligible for a total laryngectomy. Patients
were randomized between an experimental arm starting with
TPF (docetaxel at 75 mg/m2 on day 1, cisplatin at 75 mg/m2
on day 1, and 5-fluorouracil at a dose of 750 mg/m2 by 120-h
continuous infusion over 5 days) compared with the classical PF
one (cisplatin 100 mg/m2 on day 1 and 5-fluorouracil given at a
dose of 1,000 mg/m2 by 120-h continuous infusion over 5 days).
Three cycles at a 3-week interval were planned in the two arms
and responders were treated by RT while non-responders had
total laryngectomy and postoperative RT. Laryngeal preservation
(larynx in place without tumor, tracheostomy or feeding tube)
was the primary end-point. Overall survival and progression-free
survival were secondary endpoints. two hundred twenty patients
were enrolled, of whom 213 were eligible (110 in the TPF arm
and 103 in the PF arm).
The first evaluation revealed that in the TPF arm 69 patients
(62.7%) could receive the complete treatment without delay or
dose reduction vs. 33 patients (32%) in the PF arm. The response
rates were 80% with TPF arm and 59.2% with PF (P= 0.002). As
a result, laryngeal preservation was offered to 78.8% of patients
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in the TPF arm vs. 55.3% in the PF arm. With a median follow-
up of 36 months, the 3-year actuarial laryngeal preservation rate
was 70.3% in the TPF arm vs. 57.5% in the PF arm (P = 0.002)
(Table 1). However, there were no significant differences in terms
of survival (14).
The long-term evaluation confirmed the initial results. The 5-
year and 10-year laryngeal preservation rates were 74.0% (95%
CI: 64–82%) vs. 58.1% (95% CI: 47–68%) and 70.3% (95% CI:
58–80%) vs. 46.5% (95% CI: 31–63%, P= 0.01) with TPF and PF,
respectively. There was no significant difference in 5-year and 10-
year overall survival, or disease-free survival. Of note there were
fewer grade 3–4 late toxicities in the TPF arm (9.3%) than in the
PF arm (17.1%, P= 0.038) (15).
Of note, in this trial it was left to institutional policies to deliver
either radiotherapy alone or concurrent chemoradiotherapy in
responders. Seventeen patients in the TPF arm and 9 patients in
the PF arm received concurrent chemo-radiation. The impact of
this on the overall study results is unknown.
THE RADIATION THERAPY ONCOLOGY
GROUP (RTOG) 91-11 TRIAL WITH
CONCURRENT CHEMORADIOTHERAPY
In the Unites States, the RTOG and the Head and Neck
Intergroup conducted a three-arm randomized trial comparing
the standard alternative to total laryngectomy validated by
previous trials (induction PF chemotherapy followed by
radiotherapy) vs. radiotherapy with concurrent cisplatin vs.
radiotherapy alone in 547 previously untreated patients with
locally advanced larynx cancer (16). Laryngectomy-free survival
was the primary endpoint while laryngeal preservation (larynx
in place) and survival were secondary endpoints. This study
excluded patients with large-volume stage T4 disease defined as
tumor penetrating through the cartilage or extending more than
1 cm into the base of tongue. In total only 10% of patients enrolled
in 91–11 trial had stage T4 tumors.
In the first report no difference was found in acute toxicity
during the radiotherapy between the induction chemotherapy
and the radiotherapy alone arm. The 2-year and the 5-year
estimates for laryngectomy-free survival were, respectively, 59
and 43% in the induction arm, 66 and 45% in the concurrent arm,
and 53 and 38% in the radiotherapy alone arm. The difference
was not significant between the induction and the concurrent
arms. The 2-year and 5-year overall survival did not differ
significantly according to the treatment arm. The rate of laryngeal
preservation at a median follow-up of 3.8 years was significantly
higher in the concurrent arm (84%) when compared with the
induction arm (72%, P = 0.005) or with the radiotherapy alone
arm (67%, P < 0.001) (16).
The long-term analysis with a median follow-up of 10.8 years
in surviving patients confirmed that there was no significant
difference in late toxicity between the three arms. The two
chemotherapy arms significantly improved laryngectomy-free
survival compared with radiotherapy alone without significant
difference between these two arms. Overall survival did not differ
significantly between the treatment arms, although there was a
trend for a higher survival in the induction arm. However the
rate of deaths not related to the study cancer was significantly
higher in the concurrent arm compared with the induction one
(69.8 vs. 52.8%, respectively, at 10 years, P = 0.03). With regards
to laryngeal preservation, the difference favoring the concurrent
arm with regards to the laryngeal preservation persisted at 10
years 67.5% (95% CI: 60.4–74.6%) in the induction arm, 81.7%
(95% CI: 75.9–87.6%) in the concurrent arm, and 63.8% (95%
CI: 56.5–71.1%) in the radiotherapy alone arm (17) (Table 1).
Again, there were fewer distant metastases in the two arms with
chemotherapy when compared with radiotherapy alone.
Long-term results of 91–11 confirm that CRT is a standard
treatment option but also raise concerns about late effects from
CRT leading to increased number of non-cancer related deaths.
TRIALS INTEGRATING CETUXIMAB AND
COMBINING INDUCTION
CHEMOTHERAPY FOLLOWED BY
CONCURRENT CHEMORADIOTHERAPY
A randomized trial had shown that adding cetuximab to RT
significantly provided higher survival and loco-regional control
over RT alone (18). Therefore, further study of cetuximab in
combined modality regimens was worth exploring.
The GORTEC “TREMPLIN Trial”
An experimental approach with induction chemotherapy
followed by concurrent CRT was tested in the laryngeal
preservation setting. Anticipating an overall toxicity that could
compromize the larynx function, and taking into account
the results of the radiotherapy plus cetuximab trial (18), the
GORTEC conducted a randomized phase II study to assess
what could be the best post-induction protocol in 153 patients
with laryngeal or hypopharyngeal cancer amenable to a
total laryngectomy (19).
Patients received 3 cycles of TPF and responders were
randomized between RT plus cisplatin (100 mg/m2 on day 1, 22,
and 43 of RT) and RT plus cetuximab (a loading dose of 400
and 250 mg/m2 per week during RT. The primary endpoint was
laryngeal preservation (no residual disease justifying immediate
salvage laryngectomy) 3 months after the end of treatment.
The secondary endpoints were larynx function preservation and
overall survival 18 months after the end of treatment.
Of the 153 enrolled patients, 116 were randomized (60 in
the cisplatin arm, and 56 in the cetuximab arm). Substantial
acute toxicity was observed in both arms, in particular in-field
skin toxicity in the cetuximab arm and renal, hematological,
and performance status alteration in the cisplatin arm. Limiting
acute toxicity led to protocol modification in more patients
in the cisplatin arm than in the cetuximab arm (71 and 43
vs. 71%, respectively). Except for grade 1 renal toxicity, late
toxicity did not differ significantly between both arms. At last
examination, there were fewer local recurrences in the cisplatin
arm (8 patients) compared with 12 patients in the cetuximab arm,
but successful salvage surgery could be performed only in the
cetuximab arm.
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TABLE 1 | Key phase III trials of laryngeal preservation strategies.
Study Patients
enrolled
Investigational
regimen(s)
Control
regimen
Primary endpoint(s) Results Comments
RTOG
91-11
547
(larynx 100%)
a) CRT
c) RT
b) PF followed
by RT
Laryngeal preservation
Laryngectomy-
free survival
Laryngeal preservation
rates at 5 years (a vs. b
vs. c): 84% vs. 71% vs.
66%
Laryngectomy-free
survival at 5 years (a vs.
b vs. c): 47% vs. 44%
vs. 34%
Overall survival at 5
years (a vs. b vs. c):
55% vs. 58% vs. 54%
CRT and
PF followed by RT are
superior to RT alone
GORTEC
2000-01
213
(larynx, 46%;
hypopharynx,
54%)
TPF followed
by RT*
PF followed
by RT*
Laryngeal preservation Laryngeal preservation
rates (actuarial) at 3
years:
70.3 vs. 57.5%
No difference in overall
survival (60% at 3 years
in both arms)
TPF is more effective
than PF
*16% of patients in the PF arm and 20% of patients in the TPF arm received concurrent chemotherapy during RT. CRT, chemoradiotherapy; RT, radiotherapy; TPF, cisplatin, docetaxel,
5-fluorouracil; PF, cisplatin, 5-fluorouracil.
There was no significant difference in laryngeal preservation
at 3 months: 95% (95% CI: 86–98%) in the cisplatin arm vs.
93% (95% CI: 83–97%) in the cetuximab arm. There was no
obvious difference in secondary endpoints at 18 months as well.
The larynx function preservation was 87% (95% CI: 76–93%) in
the cisplatin arm vs. 82% (95% CI: 70–90%) in the cetuximab
arm. The overall survival was 92% in the cisplatin arm (95% CI:
82–96%) and 89% (95% CI: 79–95%). At a median follow-up
of 36 months overall survival was 75% (95% CI: 62–85%) and
73% (95% CI: 60–84%) in the cisplatin arm and cetuximab arm,
respectively. These data must be considered with caution as they
related to the population selected after induction chemotherapy
(i.e., 75% of the overall population).
As the composite end-point of laryngoesophageal
dysfunction-free survival had been described after the trial
was initiated and had been published at the time of the trial
evaluation, this end-point was tested. Two years after the end of
treatment there was no significant difference in that end-point:
79% (95% CI: 67–89%) with cisplatin vs. 72% (95% CI: 65–89%)
with cetuximab (19).
The conclusion was that there was no signal that one arm was
superior over the other one, and none appeared to be superior
to induction TPF followed by RT alone as found in the above-
mentioned GORTEC 2000-01 trial.
After induction TPF it is difficult to administer high-dose
cisplatin due to cumulative toxicities. RT plus carboplatin
or cetuximab have been explored but we do not have any
data coming from trials specifically designed for laryngeal
preservation. However, whether the addition of a systemic agent
to RT after TPF induction is superior to RT alone is unproven.
The German “DeLOS-II Trial”
The German Larynx Organ preservation Study group (DeLOS)
conducted another randomized phase II study assessing the
place of cetuximab in laryngeal preservation for patients with
larynx or hypopharynx cancer (20). The initial trial design
was to compare induction TPF followed by RT with TPF
plus cetuximab (E) followed by RT plus cetuximab. Due to
4 treatment-related deaths among the first 64 patients, the
protocol was amended and fluorouracil was omitted from
induction chemotherapy in both arms. There were no further
treatment-related deaths thereafter. The evaluation was made
after one cycle and responders continued the protocol while
non-responders went to laryngectomy. The primary objective
was a 2-year functional laryngectomy-free survival (fLFS)
above 35%.
Of the 180 patients randomized in the trial, 173 fulfilled
the intent to treat criteria. At final examination, the objective
response rates in the arm without cetuximab were 79.1% in
patients who had received PF, and 94.7% in patients who
had received TP. In the arm with cetuximab they were 80%
in patients who had received TPFE, and 94.9% in patients
with TPE, 94.9% (i.e., similar to TPF). The primary objective
was similarly met in both arms: 44.7% in the arm without
cetuximab and 46.6% in the cetuximab arm (OR:0.9268,
95% CI:0.5094–1.6863). There was no difference in 2-year
overall survival: 68.2% in the arm without cetuximab, and
69.3% in the cetuximab arm (OR:0.9508, 95% CI:0.4997–
1.8091).
The conclusions were that despite being accompanied
by an elevated frequency in adverse events, the induction
chemotherapy with TPF/TP plus cetuximab was feasible but
showed no superiority to induction chemotherapy with TPF/PF
alone regarding LFS and OS at 24 months (20).
CONCLUSIONS
To date, only two strategies for laryngeal preservation in
previously untreated patients with locally advanced laryngeal
Frontiers in Oncology | www.frontiersin.org 5 May 2019 | Volume 9 | Article 419
Argiris and Lefebvre Laryngeal Preservation Strategies
and hypopharyngeal cancers have been validated: induction
TPF followed by RT alone (GORTEC 2000-01) and RT
with concurrent cisplatin (RTOG 91-11). Whereas, both
approaches have been assessed in laryngeal cancers, only
induction chemotherapy-based protocols have been evaluated
in hypopharyngeal cancers. The RTOG 91–11 trial did not
contain an arm with TPF induction as this trial was initiated
before the TPF induction regimen was proved to be superior
to PF in the GORTEC 2000-01 trial. As a result, there
is a need to compare the RTOG concurrent arm and
the TPF arm of the GORTEC trial. The ongoing French
phase III trial (GORTEC 2014-03-SALTORL, clinicaltrials.gov
NCT03340896) is comparing induction TPF followed by RT
in responders vs. concurrent cisplatin-based chemoradiotherapy
with the composite end-point of laryngoesophageal dysfunction-
free survival as primary end-point. Eligible are patients with
stage T2-3, N0-2 laryngeal, or hypopharyngeal SCC requiring
total laryngectomy. Patients with pretreatment poor laryngo-
esophageal function (in particular those requiring a pre-
treatment tracheostomy) should be treated by upfront TL.
The decision of enrolling a patient in a laryngeal preservation
protocol must be taken by a multidisciplinary tumor board.
We acknowledge that there is significant variability between
centers worldwide regarding the applicability of clinical trial
results on laryngeal preservation approaches. In general, patients
eligible for a laryngeal preservation strategy are patients with
advanced larynx and hypopharynx cancers who are not eligible
for partial surgery. Of importance, bulky T4 tumors extending to
the post-cricoid area are not eligible for laryngeal preservation.
Also, patients who are not candidates to receive cisplatin should
not be generally be considered for a laryngeal preservation
approach given the low success rates with RT alone. Treatment
with RT plus cetuximab is not a validated approach for laryngeal
preservation and may result in inferior outcomes compared to
RT plus cisplatin.
To transition the outcomes of these trials into clinical
practice it is important to strictly follow the study protocols with
respect to initial work-up and eligibility criteria, chemotherapy
protocols, prophylaxis/management of treatment-induced
toxicity, response to treatment evaluation, as well as schedule
and tools for post-treatment follow-up. Such approaches require
experienced multidisciplinary teams.
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